
Documentation submitted for perusal to the Ordinary General Meeting of Shareholders of Ryvu Therapeutics S.A. scheduled for 28 June 2021

On 16th of March 2021 the Company published its annual report, which included, among others, the following items:

- Management Board report on Ryvu Therapeutics S.A. activities in 2020;
- Financial statement of Ryvu Therapeutics S.A. for 2020;
- Audit report concerning the financial statement of Ryvu Therapeutics S.A. for 2020;

This documentation has been published on www.ryvu.com and is also available at the Company headquarters.

THE RESOLUTIONS, the Supervisory Board Report on The Supervisory Board Activity in 2020 and Supervisory Board Report on Remuneration of Management Board and Supervisory Board of Ryvu Therapeutics S.A. for years 2019 and 2020 submitted to the Ordinary General Meeting of Shareholders for the fiscal year 2020 [*as adopted by circulation using means of electronic communication*]:

**Resolution no. 1
of the Supervisory Board of Ryvu Therapeutics S.A.
of 1st of June 2021**

concerning assessment of the Ryvu Therapeutics S.A. financial statement for the financial year 2020, Management Board report on the operations of Ryvu Therapeutics S.A. for the financial year 2020, Management Board's proposal regarding the net loss of Ryvu Therapeutics S.A. for the financial year 2020 and submission to the General Meeting of Supervisory Board Report containing results of assessment of Ryvu Therapeutics S.A. financial statement for the financial year 2020, Management Board report on the operations of Ryvu Therapeutics S.A. for the financial year 2020, Management Board's proposal regarding the net loss of Ryvu Therapeutics S.A. for the financial year 2020

Acting in compliance with Art. 382 § 3 of the Commercial Companies Code, the Supervisory Board of Ryvu Therapeutics S.A. ("**Company**") hereby resolves as follows:

§ 1

1. Following assessment of the Company financial statement for 2020 and its corresponding audit report and Management Board report on the operations of Ryvu Therapeutics S.A. for the financial year 2020, the Supervisory Board has determined that the Company financial statement for 2020 and Management Board report on the operations of Ryvu Therapeutics S.A. for the financial year 2020 are materially consistent with Company accounts, as well as being factually correct.
2. The Supervisory Board submits the Company financial statement for 2020 and Management Board report on the operations of Ryvu Therapeutics S.A. for 2020 to the General Meeting and recommends its approval.
3. Following assessment of the Company financial statement for 2020 and the Management Board recommendation concerning allocation of net loss, as expressed in Ryvu Therapeutics S.A. Management Board proposal as of 8 April 2021, the Supervisory Board recommends that the net loss in the amount of 31.687.588 PLN of the previous financial year 2020 shall be carried forward and financed from profits of upcoming years.
4. The Supervisory Board submits to the General Meeting its report which contains the results of its assessment of the Company financial statement, Management Board report on the operations of Ryvu Therapeutics S.A. for the financial year 2020 and the Management Board recommendation concerning allocation of net loss obtained in 2020, as appended to this resolution.

§ 2

The resolution enters into force on the date of its adoption.

Ryvu Therapeutics S.A. Supervisory Board report concerning the outcome of assessment of the Company financial statement for 2020, Management Board report on the operations of Ryvu Therapeutics S.A. for the financial year 2020 and the Management Board recommendation concerning allocation of net loss obtained in 2020

- I. Assessment of the Ryvu Therapeutics S.A. financial statement and Management Board report on the operations of Ryvu Therapeutics S.A. for the financial year 2020

In the course of discharging its statutory duties, on 14 June 2019 the Supervisory Board adopted resolution selecting Ernst & Young Audyt Polska sp. z o.o. sp. k. with its registered office in Warsaw as the independent auditor contracted to audit the Company financial statement for the period between 1 January and 31 December 2020.

The object of the audit was the financial statement for the period between 1 January and 31 December 2020, prepared on 12 March 2021.

The Management Board communicated the outcome of the audit to the Supervisory Board and provided a copy of the audit report prepared by the aforementioned auditor.

With regard to the Company financial statement, on 15 of March 2021 the licensed auditor issued an opinion declaring that the financial statement:

- gives a true and fair view of the financial position of the Company as of December 31, 2020 and its financial performance and its cashflows for the period from January, 1 2020 to December 31, 2020 in accordance with required applicable rules of the Accounting Act dated September, 29 1994 and the adopted accounting policies,
- are in respect of the form and content in accordance with legal regulations governing the Company and the Company's Articles of Association,
- have been prepared based on properly maintained accounting records, in accordance with the Chapter 2 of the Accounting Act.

The presented outcome is consistent with a separate report issued for the Audit Committee on April, 8 2021.

The presented outcome formed the basis of the Supervisory Board assessment of the Company financial statement for 2020.

Following assessment of the Company financial statement for 2020, the Supervisory Board hereby declares that the financial statement is materially consistent with the Company accounts and records, as well as being factually correct.

Following assessment of the Management Board report on the operations of Ryvu Therapeutics S.A. for 2020, the Supervisory Board hereby declares that the Management Board report on the operations of Ryvu Therapeutics S.A. for 2020 is materially consistent with the Company accounts and records, as well as being factually correct.

- II. Assessment of the Ryvu Therapeutics Management Board recommendation concerning allocation of net loss obtained in 2020

Following assessment of the Company financial statement for 2020 and the Management Board recommendation concerning allocation of net loss, as expressed in Ryvu Therapeutics S.A. Management Board statement as of 8 April 2021, submitted to the Supervisory Board and to the General Meeting, the Supervisory Board recommends that the net loss in the amount of 31.687.588 PLN of the previous financial year 2020 shall be carried forward and financed from profits of upcoming years.

Resolution no. 2
of the Supervisory Board of Ryvu Therapeutics S.A.
of 1st of June 2021
concerning approval and submission to the General Meeting of the report on Supervisory

Board activities in 2020, along with an assessment of the situation of Ryvu Therapeutics S.A. in 2020, including the assessment of the Company's internal control and risk mitigation systems, compliance, internal audit, fulfilment of disclosure obligations and statement regarding the functioning of the Audit Committee and the independent Auditor

The Supervisory Board of Ryvu Therapeutics S.A. with its registered office in Cracow (the "**Company**") pursuant to Rule No. II.Z.10 of the Code of Best Practices for WSE Listed Companies resolves as follows:

§ 1

1. The Supervisory Board hereby approves the report on Supervisory Board activities in 2020, along with an assessment of the situation of Ryvu Therapeutics S.A. in 2020, including the assessment of the Company's internal control and risk mitigation systems, compliance, internal audit, fulfilment of disclosure obligations and statement regarding the functioning of the Audit Committee and the independent Auditor. The Report on Supervisory Board activities in 2020 is attached to this resolution.
2. The Supervisory Board submits the Report on Ryvu Therapeutics S.A. Supervisory Board activities in 2020 to the General Meeting with a recommendation for its approval.

§ 2

The resolution enters into force on the date of its adoption.

Supervisory Board Report of RYVU THERAPEUTICS S.A. concerning activities in the fiscal year 2020, along with an assessment of the situation of Ryvu Therapeutics S.A. in 2020, including the assessment of the Company's internal control and risk mitigation systems, compliance, internal audit, fulfilment of disclosure obligations and statement regarding the functioning of the Audit Committee and the independent Auditor

I. Composition and activities of the Supervisory of Ryvu Therapeutics S.A. ("Company") in 2020.

As of December 31, 2020, the composition of the Supervisory Board of Ryvu Therapeutics S.A. was as follow:

- 1) Piotr Romanowski - Chairman of the Supervisory Board
- 2) Tadeusz Wesolowski - Vice Chairman of the Supervisory Board
- 3) Rafał Chwast - Member of the Supervisory Board
- 4) Axel Glasmacher - Member of the Supervisory Board
- 5) Colin Goddard - Member of the Supervisory Board
- 6) Jarl Ulf Jungnelius - Member of the Supervisory Board
- 7) Thomas Turalski - Member of the Supervisory Board

The conditions for independence within the meaning of Annex II to the European Commission Recommendation 2005/162 / EC of 15 February 2005 regarding the role of non-executive or supervisory directors of listed companies and the (supervisory) board committee, were met by the following members of the Supervisory Board: Mr. Piotr Romanowski, Mr. Rafał Chwast, Mr. Axel Glasmacher, Mr. Colin Goddard, Mr. Jarl Ulf Jungnelius and Mr. Thomas Turalski.

The composition and diverse competencies of the members of the Supervisory Board guarantee effective supervision over all areas of the Company's operations. Therefore, in the Supervisory Board's opinion, its current composition is sufficient to ensure performance of all duties to which a supervisory board of a public company is legally obligated.

The composition of the Supervisory Board and its activities were in accordance with generally applicable law, including the Commercial Companies Code, the Company's Articles of Association and the Regulations of the Supervisory Board as well as recommendations and principles resulting from Good Practices of WSE Listed Companies.

In 2020, four live meetings of the Company's Supervisory Board were held, and therefore the legal requirements set forth in art. 389 § 3 of the Polish Commercial Companies Code regarding the frequency

of meetings were met. Additionally, the Supervisory Board conducted its affairs by adopting resolutions outside of meetings by adopting resolutions by circulation. A significant portion of Supervisory Board activities were performed with the use of remote communication tools, enabling better oversight of current Company's affairs.

In 2020, in discharging its legal and statutory duties the Supervisory Board maintained ongoing oversight of all matters affecting the Company throughout 2020 and exercised constant supervision over the Company's operations in all areas of its operations, providing the Company's Management Board with necessary consultations regarding strategic decisions for the Company. In particular, the Supervisory Board assessed the plans of the Management Board concerning business strategies implemented by the Company, as well as day-to-day activities of the Company, and its financial condition.

The Supervisory Board activities in 2020 included in particular:

- ongoing supervision over the Company's operations in terms of setting strategic goals,
- granting and changing the remuneration of Management Board Members, as well as deciding on the payment of additional remuneration (bonuses),
- assessment of the Management Board report on the operations of Ryvu Therapeutics S.A. for the financial year 2019,
- assessment of the financial statements of Ryvu Therapeutics S.A. for the financial year 2019,
- assessment of the Management Board proposal to cover the net loss of Ryvu Therapeutics S.A. for the financial year 2019,
- adoption of the Supervisory Board Report on operations in 2019.

Throughout 2020 the control and oversight duties of the Supervisory Board of Ryvu Therapeutics S.A. were discharged faithfully and with due diligence. The Supervisory Board positively assesses its work in 2020.

II. Composition and activities of the Audit Committee in 2020

As of December 31, 2020, the composition of the Audit Committee of Ryvu Therapeutics S.A. was as follows:

- 1) Mr. Rafał Chwast - Chairman of the Audit Committee
- 2) Mr. Piotr Romanowski - Member of the Audit Committee
- 3) Mr. Tadeusz Wesółowski - Member of the Audit Committee
- 4) Mr. Jarl Jungnelius - Member of the Audit Committee

In 2020, there were the following changes in the composition of the Audit Committee:

- on September 19, 2020, Mr. Wojciech Chabasiewicz tendered his resignations from the office,
- on January 24, 2021 Mr. Jarl Jungnelius was appointed by the Supervisory Board to the Audit Committee.

Members of the Audit Committee in the indicated composition met the independence criteria and other requirements specified in art. 129 section 1, 3, 5 and 6 of the Act of 11 May 2017 on statutory auditors, audit companies and public oversight.

During the reporting period the Audit Committee held sessions and also carried out its work using remote communication tools.

With regard to duties of the Audit Committee, the Audit Committee oversaw the financial reporting process and discharged its auditing obligations, including reviews of Company financial statements prior to their publication, and periodic meetings with auditors.

In addition, in the financial year 2020, a Remuneration Committee was established in the Supervisory Board. The Company's Remuneration Committee:

- 1) Piotr Romanowski – Chairman of the Remuneration Committee
- 2) Colin Goddard – Member of the Remuneration Committee
- 3) Axel Glasmacher – Member of the Remuneration Committee
- 4) Thomas Turalski – Member of the Remuneration Committee

III. Assessment of the situation of Ryvu Therapeutics S.A. in 2020, including the assessment of the internal control and risk mitigation systems, compliance and internal audit

The Management Board of the Company is responsible for its internal control and risk mitigation systems and for periodic assessment of risk factors which may affect the Company during the given fiscal year. The Management Board of the Company is responsible for effective operation of its internal control system in preparing the Company's financial statements. It is also responsible for ensuring the correctness of said financial statements during preparation and publication of periodic reports.

Internal control and risk management in relation to the process of preparing the Company's financial statements are implemented in accordance with the applicable internal procedures for preparing and approving financial statements. The Company maintains documentation describing its accounting principles, which includes, among others, information on how assets and liabilities are valued and how to determine the financial result, how to keep accounting books, the data protection system and their collections. Financial data reported in these documents is derived from the Company's accounting system eNova which registers financial data in line with the Company's accounting policy.

The financial statements are prepared by employees of the accounting department with the support of the controlling department, under the control of the Chief Accountant and the Financial Director, within Shared Services Center ("SSC") as part of the provision of joint services pursuant to an agreement entered into between the Company and Selvita S.A. and Selvita Services sp. z o.o. The financial statements are audited by an independent auditor selected by the Company's Supervisory Board (currently E&Y Audyt Polska sp.z o.o.sp.k.), while the semi-annual reports are reviewed by an independent auditor.

In the Supervisory Board's opinion, the internal control system and risk mitigation strategies described above are consistent. As such, the Supervisory Board deems the internal control system and risk mitigation strategies applied in 2020 appropriate and believes that they materially reduce key risks which may threaten Company operations.

The Supervisory Board assesses the internal control system and risk management significant for the Company as fulfilling its tasks in a diligent manner.

The separate unit performing internal audit and compliance functions does not operate within the Company. Aforementioned duties and obligations are performed for the benefit of the Company by Selvita S.A. and Selvita Services sp. z o.o. under SSC Agreement. The Supervisory Board assesses the internal audit and compliance functions as adequate for fulfilling Company's tasks in a diligent manner.

IV. Information on obligations regarding the application of corporate governance principles as set out in the Good Practices of WSE Listed Companies, Stock Exchange Regulations and in the Regulation on current and periodic information.

Pursuant to § 29 para. 3 of the Exchange Rules, if a specific corporate governance rule is not applied permanently or is incidentally violated, the issuer is required to publish a report containing information about what rule is not applied or has not been applied, what were the circumstances and reasons for not applying the rule and how the issuer intends to remove any consequences of not applying the rule or what steps it intends to take to reduce the risk of not applying the rule in the future. The report should be published on the issuer's official website and in a similar mode to that used for submitting current reports. The obligation to publish the report should be carried out immediately after the issuer's reasonable belief that the principle is not applied or that it will not be applied, and in any case immediately after the occurrence of an event constituting a violation of the specific corporate governance principle. Reports on the application of detailed corporate governance rules referred to in § 29 para. 3 of the Stock Exchange Regulations, are transmitted via the Electronic Information Database.

The Regulation on current and periodic information specifies which information should be included in the corporate governance statement constituting a separate part of the company's annual report.

The Supervisory Board assesses that the Company correctly fulfills the disclosure obligations related to the application of corporate governance principles specified in the legal provisions indicated above.

In the financial year 2020, the Company complied with all corporate governance principles contained in the document 'Good Practices of WSE Listed Companies', except for the following recommendations: IV.R.2, IV.R.3, IV.Z.2. and the rules: I.Z.1.10, I.Z.1.16, I.Z.1.20., I.Z.2.

Precise information on the principles and recommendations not applied by the Company, together with detailed justification, is included in the Company's annual report for 2020, which was published and is available on the Company's website at: www.rylvu.com.

In addition, in 2020, the Company did not permanently or incidentally violate the corporate governance rules, which would require reporting under § 29 para. 3 of the Stock Exchange Regulations.

The Supervisory Board familiarized itself with the statement on the application of corporate governance, considering that this statement describes the issues of corporate governance in a detailed and comprehensive manner and contains the information required by the Regulation on current and periodic information.

In the opinion of the Supervisory Board, the information made public by the Company complies with the requirements arising from legal provisions and fairly presents the state of its compliance with the corporate governance principles.

Throughout 2020 the Company conducted its business in a manner consistent with legal regulations applicable to public companies, including corporate governance law. In the Supervisory Board's opinion, the Company met its disclosure obligations relating to compliance with corporate governance law.

V. Assessment of sponsorships and other charitable activities

As part of its Corporate Social Responsibility, Ryvu Therapeutics, intends to build long-term relationships with charity organizations based mainly in Krakow, and making an impact on both local and national communities' lives.

Company supports UNICORN Charitable Association in Krakow, a charitable organization established in 1999, which supports oncology patients and their families. The association runs the first Polish psycho-oncology centre – a place where patients get professional psychological help to support them getting through the oncology diagnosis and treatment.

Ryvu Therapeutics took also part in a Krakow charity run organized by Poland Business Run Foundation, supporting people with mobility impairment in overcoming the social barriers. Also, the foundation promotes the awareness about disabilities and tries to change the social perception of disabled people.

Furthermore, the Company cooperates with the "Piekne Anioly" Association helping children and youth living in tough conditions. Ryvu Therapeutics also supports Krakow St. Lazarus Hospice, which provides palliative care and support. Also, the Company cooperates with the "PRO CHEMIA" Foundation at the Faculty of Chemistry at Jagiellonian University. The foundation aims to support the Faculty to renew its material base, mostly state-of-the-art laboratory equipment for research and development.

VI. Statement of the Supervisory Board of Ryvu Therapeutics S.A. regarding the functioning of the Audit Committee and the Auditor

The Supervisory Board of Ryvu Therapeutics S.A. with its registered office in Kraków (the "Company") acting pursuant to § 70.1.7 and 8 and § 71.1.7 and 8 of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information published by issuers of securities and conditions for recognizing as equivalent information required by the laws of a non-member state (Journal of Laws of 2018 item 757) declares that in the Company:

- a) the provisions regarding the establishment, composition and functioning of the Audit Committee, including the fulfillment by its members of the independence criteria and requirements regarding the possession of knowledge and skills in the industry in which the Company operates, as well as in the field of accounting and auditing financial statements, are complied with,
- b) the Audit Committee performed the tasks of the Audit Committee provided for in applicable regulations,
- c) the Auditor, i.e. Ernst & Young Audyt Polska sp. z o.o. sp.k. and members of the audit team met the conditions for preparing an independent audit report on the separate annual financial statements in accordance with applicable regulations, professional standards and ethics,
- d) at Ryvu Therapeutics S.A. the applicable regulations related to the rotation of the audit firm and key statutory auditor and the mandatory grace periods are complied with,
- e) Ryvu Therapeutics S.A. has a policy and procedures of selection an audit firm to carry out a statutory audit of the Company financial statements and the Policy for the provision of additional services by the audit firm, an entity affiliated to the audit firm or a member of its network.

Resolution no. 3
of the Supervisory Board of Ryvu Therapeutics S.A.
of 1st of June 2021

concerning approval and submission to the General Meeting of the Supervisory Board Report on Remuneration of Management Board and Supervisory Board of Ryvu Therapeutics S.A. for years 2019 and 2020

Pursuant to article 90g sec.1 and 6 of the Offering Act, Supervisory Board resolves as follows:

§ 1

1. The Supervisory Board hereby approves the Report on Remuneration of Management Board and Supervisory Board of Ryvu Therapeutics S.A. for years 2019 and 2020. The Report is attached to this resolution.
2. The Supervisory Board submits Supervisory Board Report on Remuneration of Management Board and Supervisory Board of Ryvu Therapeutics S.A. for years 2019 and 2020 to the General Meeting for its assessment.

§ 2

The resolution enters into force on the date of its adoption.

Resolution no. 4
of the Supervisory Board of RYVU THERAPEUTICS S.A.
of 1st of June 2021

concerning submission to the General Meeting of a recommendation for a vote of acceptance to the President of the Management Board, Mr. Paweł Przewięźlikowski, on account of the performance of his duties in the 2020 fiscal year

Pursuant to Rule No. II.Z.11 of the Code of Best Practices for WSE Listed Companies, the Supervisory Board hereby resolves as follows:

§ 1

Having assessed the performance of duties by Mr. Paweł Przewięźlikowski, President of the Management Board, the Supervisory Board submits to the General Meeting a recommendation for a vote of acceptance to Mr. Paweł Przewięźlikowski on account of the performance of his duties in the 2020 fiscal year between 1 January and 31 December 2020.

§ 2

The resolution enters into force on the date of its adoption.

Resolution no. 5
of the Supervisory Board of RYVU THERAPEUTICS S.A.
of 1st of June 2021

concerning submission to the General Meeting of a recommendation for a vote of acceptance to the Vice President of the Management Board, Mr. Krzysztof Brzózka, on account of the performance of his duties in the 2020 fiscal year

Pursuant to Rule No. II.Z.11 of the Code of Best Practices for WSE Listed Companies, the Supervisory Board hereby resolves as follows:

§ 1

Having assessed the performance of duties by Mr. Krzysztof Brzózka, Vice President of the Management Board, the Supervisory Board submits to the General Meeting a recommendation for a

vote of acceptance to Mr. Krzysztof Brzózka on account of the performance of his duties in the 2020 fiscal year between 1 January and 31 December 2020.

§ 2

The resolution enters into force on the date of its adoption.

**Resolution no. 6
of the Supervisory Board of RYVU THERAPEUTICS S.A.
of 1st of June 2021**

**concerning submission to the General Meeting of a recommendation for a vote of acceptance
to the Vice President of the Management Board, Ms. Setareh Shamsili, on account of the
performance of his duties in the 2020 fiscal year**

Pursuant to Rule No. II.Z.11 of the Code of Best Practices for WSE Listed Companies, the Supervisory Board hereby resolves as follows:

§ 1

Having assessed the performance of duties by Ms. Setareh Shamsili, , the Supervisory Board submits to the General Meeting a recommendation for a vote of acceptance to Ms. Setareh Shamsili on account of the performance of her duties in the 2020 fiscal year as a Member of the Management Board between 1 January 2020 and 31 August 2020 and as Vice President of the Management Board between 31 August and 31 December 2020.

§ 2

The resolution enters into force on the date of its adoption.

**Resolution no. 7
of the Supervisory Board of RYVU THERAPEUTICS S.A.
of 1st of June 2021**

**concerning submission to the General Meeting of a recommendation for a vote of acceptance
to the Management Board Member, Mr. Kamil Sitarz, on account of the performance of
his duties in the 2020 fiscal year**

Pursuant to Rule No. II.Z.11 of the Code of Best Practices for WSE Listed Companies, the Supervisory Board hereby resolves as follows:

§ 1

Having assessed the performance of duties by Mr. Kamil Sitarz, Member of the Management Board, the Supervisory Board submits to the General Meeting a recommendation for a vote of acceptance to Mr. Kamil Sitarz on account of the performance of his duties in the 2020 fiscal year between 23 November 2020 and 31 December 2020.

§ 2

The resolution enters into force on the date of its adoption.

**Resolution no. 8
of the Supervisory Board of Ryvu Therapeutics S.A.
of 1st of June 2021**

**concerning adoption of the Incentive Scheme Regulations of Ryvu Therapeutics S.A. for the
years 2021-2024**

Pursuant to § 1 clause 7 of the Resolutions no. 4 of the Extraordinary General Meeting of Ryvu Therapeutics S.A. as of May 17, 2021, authorizing the Supervisory Board to adopt detailed rules and conditions for the implementation of the Ryvu Therapeutics S.A. Incentive Program for the years 2021-2024, Supervisory Board resolves as follows:

§ 1

The Incentive Scheme Regulations of Ryvu Therapeutics S.A. are hereby adopted for the years 2021-2024, as attached hereto.

§ 2

The resolution enters into force on the date of its adoption.

Resolution no. 9
of the Supervisory Board of Ryvu Therapeutics S.A.
of 1st of June 2021

on the approval of the List of Eligible Persons - Members of the Management Board of Ryvu Therapeutics S.A. - to participate in the Ryvu Therapeutics S.A. Incentive Program for the years 2021-2024, as well as granting authorization to sign Incentive Scheme Participation Agreements and any other document required for the purpose of execution of the program with Members of the Management Board of Ryvu Therapeutics S.A.

Acting pursuant to § 1 sec. 7 of the Resolution no. 4 of the Extraordinary General Meeting of Ryvu Therapeutics S.A. as of May 17, 2021, § 6 sec. 2 in connection with § 6 sec. 6 of the Incentive Scheme Regulations of Ryvu Therapeutics S.A. for the years 2021-2024, as well as art. 379 §1 of the Commercial Companies Code, the Supervisory Board resolves as follows:

§ 1

The List of Eligible Persons - Members of the Management Board of Ryvu Therapeutics S.A. - is hereby adopted and attached hereto as Appendix to this Resolution.

§ 2

In accordance with Art. 379 § 1 of the Commercial Companies Code, in an agreement between the company and a member of the management board, the company shall be represented by the supervisory board, therefore Mr. Piotr Romanowski - Chairman of the Supervisory Board of the Company is hereby authorized to conclude, on behalf of the Company acting by the Supervisory Board *in gremio*, Incentive Scheme Participation Agreements with Members of the Management Board of Ryvu Therapeutics S.A. indicated in the List of Eligible Persons in accordance with § 1 above, as well as any other agreements (including cooperation agreements and donation agreement with Mr. Paweł Przewieźlikowski) that might be deemed necessary to execute the program and award the Shares to Eligible Persons - Members of the Management Board.

§ 3

Capitalized terms have the meaning given in the Incentive Scheme Regulations of Ryvu Therapeutics S.A. for the years 2021-2024.

§ 4

The resolution comes into force on the day of its adoption.